The chemical profile of active fraction of <scp><i>Kalimeris indica</i></scp> and its quantitative analysis

Huang, Wenping; Wen, Zhiqi; Wang, Qi; Chen, Renhao; Li, Zhifeng; Feng, Yulin; Yang, Shilin

doi:10.1002/bmc.4828

Cited by 5 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MLC primarily contains flavonoids, terpenoids, alkaloids, organic acids, and other chemical constituents. A collection of 133 compounds was gathered from previous literature studies[ 21 - 24 ]. The TCMSP was employed to search for relevant targets of the active ingredients in MLC, resulting in 204 potential targets after duplicate removal.…”

Section: Resultsmentioning

confidence: 99%

Unraveling the mechanism of malancao in treating ulcerative colitis: A multi-omics approach

Huang,

Wu,

Huang

et al. 2024

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND Malancao (MLC) is a traditional Chinese medicine with a long history of utilization in treating ulcerative colitis (UC). Nevertheless, the precise molecular mechanisms underlying its efficacy remain elusive. This study leveraged ultra-high-performance liquid chromatography coupled with exactive mass spectrometry (UHPLC-QE-MS), network pharmacology, molecular docking (MD), and gene microarray analysis to discern the bioactive constituents and the potential mechanism of action of MLC in UC management. AIM To determine the ingredients related to MLC for treatment of UC using multiple databases to obtain potential targets for fishing. METHODS This research employs UHPLC-QE-MS for the identification of bioactive compounds present in MLC plant samples. Furthermore, the study integrates the identified MLC compound-related targets with publicly available databases to elucidate common drug disease targets. Additionally, the R programming language is utilized to predict the central targets and molecular pathways that MLC may impact in the treatment of UC. Finally, MD are conducted using AutoDock Vina software to assess the affinity of bioactive components to the main targets and confirm their therapeutic potential. RESULTS Firstly, through a comprehensive analysis of UHPLC-QE-MS data and public database resources, we identified 146 drug-disease cross targets related to 11 bioactive components. The Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis highlighted that common disease drug targets are primarily involved in oxidative stress management, lipid metabolism, atherosclerosis, and other processes. They also affect AGE-RAGE and apoptosis signaling pathways. Secondly, by analyzing the differences in diseases, we identified key research targets. These core targets are related to 11 active substances, including active ingredients such as quercetin and luteolin. Finally, MD analysis revealed the stability of compound-protein binding, particularly between JUN-Luteolin, JUN-Quercetin, HSP90AA1-Wogonin, and HSP90AA1-Rhein. Therefore, this suggests that MLC may help alleviate intestinal inflammation in UC, restore abnormal lipid accumulation, and regulate the expression levels of core proteins in the intestine. CONCLUSION The utilization of MLC has demonstrated notable therapeutic efficacy in the management of UC by means of the compound target interaction pathway. The amalgamation of botanical resources, metabolomics, natural products, MD, and gene chip technology presents a propitious methodology for investigating therapeutic targets of herbal medicines and discerning novel bioactive constituents.

show abstract

Section: Resultsmentioning

confidence: 99%

Unraveling the mechanism of malancao in treating ulcerative colitis: A multi-omics approach

Huang,

Wu,

Huang

et al. 2024

World J Clin Cases

View full text Add to dashboard Cite

show abstract

“…To further elucidate the quantified marker differences among BCAVA samples from different geographical origins, a heat‐map and HCA analysis were applied to examine the quantitative data (Huang et al, 2020; Wen et al, 2019). Heat maps are the most widely utilized bioinformatic graphic displays for metabolomic data visualization, in which the relative abundance of components detected in each sample is presented through color intensity.…”

Section: Resultsmentioning

confidence: 99%

An integrated multi‐system to screen quality markers of blossom of Citrus aurantium L. var. amara Engl. via combining lipid‐lowering and expectorant assays

Zeng,

Wu,

et al. 2024

Biomedical Chromatography

Self Cite

View full text Add to dashboard Cite

The present research demonstrated that an integrated multi‐system based on the assays of lipid‐lowering and expectorant effects was used to screen quality markers of an edible and medical material—the blossom of Citrus aurantium L. var. amara Engl. (BCAVA)—and a portion of active constituents were quantified in multiple batches to provide scientific data to establish a quality standard for BCAVA. Mouse models were developed to evaluate the lipid‐lowering and expectorant effects, facilitating the investigation of medicinal parts through different polar extractions of BCAVA. Subsequently, ultra‐high‐performance liquid chromatography coupled with quadrupole time‐of‐flight mass spectrometry was utilized for the in vivo and in vitro identification of chemical profiles within the medicinal parts of BCAVA. This methodological approach led to the selection and quantification of several active compounds from 21 batches of BCAVA sourced from different geographical regions samples. Notably, the ethanol extract of BCAVA exhibited significant lipid‐lowering and expectorant effects while 183 compounds were identified in vitro and 109 in vivo, respectively. Then, five key ingredients were quantified, and the quantitative data were subjected to statistical analysis to discriminate between samples from various geographical regions. Overall, the findings underscore the significance of an integrated, assay‐based approach for the characterization and quality assessment of BCAVA.

show abstract

“…Chinese Pharmacopoeia records that K. indica has the effect of regulating the flow of vital energy, digesting food, and clearing away dampness and heat, and can be used to treat epigastric pain, dysentery, enteritis, urinary tract infection, etc., ( Wang et al, 2010 ; Wang et al, 2015 ; Wang et al, 2017 ). K. indica mainly contains phenolic acids, flavonoids, alkaloids, phytosterols, triterpenoids, volatile oils, polysaccharides, et al ( Lin et al, 2006 ; Ji et al, 2014 ; Ueda et al, 2014 ; Wang et al, 2017 ; Huang, et al, 2020 ). Pharmacological studies showed that it has anti-inflammatory and analgesic, anti-tumor, anti-virus, blood coagulation improving, and other pharmacological effects.…”

Section: Introductionmentioning

confidence: 99%

Effects of Kalimeris indica (L.) Sch Bip on colitis-associated colorectal cancer

Wang

Li²,

Cui³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Kalimeris indica (L.) Sch Bip (K. indica) is a plant of the genus Kalimeris in Asteraceae, and its whole herb can be used as medicine for the treatment of intestinal inflammatory diseases. But the mechanism is not clear. Therefore, this study was designed to explore the mechanism of K. indica (KI) in colitis-associated colorectal cancer. The expression levels of miR-31-5p and proinflammatory factors were detected using THP-1 and Caco2 cells in vitro. KI could rescue the upregulation of miR-31-5p induced by IL-6 and TNF-α in Caco2 and THP-1 cells. In LPS-stimulated PMA-differentiated THP-1 cells, KI restored miR-31-5p expression by downregulating the expression of IL-6 and TNF-α. C57BL/6 mice were used to construct CAC model through the induction of azoxymethane/dextran sulfate sodium. The successfully established CAC mice were treated with water extract of KI through intragastric administration for 5 weeks. The result showed that KI could significantly reduce the atypical hyperplasia in colon tissue, and inhibit the expression of proinflammatory factors such as IL-6, TNF, IL-11, IL-7, etc. At the same time, KI could restore the level of miR-31-5p in mice, and therefore the downstream LATS2 to inhibit the development of CAC. These above results indicate that KI is a potentially effective herb medicine to prevent CAC.

show abstract

The chemical profile of active fraction of Kalimeris indica and its quantitative analysis

Cited by 5 publications

References 6 publications

Unraveling the mechanism of malancao in treating ulcerative colitis: A multi-omics approach

Unraveling the mechanism of malancao in treating ulcerative colitis: A multi-omics approach

An integrated multi‐system to screen quality markers of blossom of Citrus aurantium L. var. amara Engl. via combining lipid‐lowering and expectorant assays

Effects of Kalimeris indica (L.) Sch Bip on colitis-associated colorectal cancer

Contact Info

Product

Resources

About